Hexapeptide GH secretagogue. Early GHRP with potent GH-releasing activity; also stimulates ghrelin (orexigenic) pathways, driving appetite increase as a notable research finding.
GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide and one of the original GHRP compounds developed. Like GHRP-2, it activates the ghrelin receptor to stimulate growth hormone release from the pituitary. It is notable for producing a particularly strong appetite-stimulating effect, which is mediated through the same ghrelin receptor in hunger-regulating brain areas.
Growth Hormone Research
GHRP-6 was among the first synthetic GH secretagogues developed and has been used extensively as a research tool. It produces reliable GH pulses and was critical in establishing that GH could be stimulated through receptors distinct from the GHRH receptor — what became known as the ghrelin receptor.
Appetite and Hunger Research
GHRP-6's strong appetite-stimulating effect has been studied in the context of cachexia (wasting associated with chronic disease or cancer) and conditions where appetite stimulation is desired. This effect is mediated through ghrelin receptor activation in hypothalamic hunger centers.
Cardiac Protection Research
Some animal research has examined GHRP-6 for cardiac protection in models of heart injury. Research suggests potential cardioprotective effects independent of GH release, through direct ghrelin receptor signaling in cardiac tissue, though this is a preclinical finding.
Reliable GH stimulation through ghrelin receptor activation, with a well-characterized research profile.
Strong appetite stimulation — more pronounced than with GHRP-2 or ipamorelin.
Historical role in discovering and characterizing the ghrelin receptor.
Some preclinical cardiac protection signals.
Not FDA-approved as a pharmaceutical product.
The strong appetite stimulation associated with GHRP-6 distinguishes it from newer, more selective compounds and is a significant consideration for any research context involving body composition. Like GHRP-2, it also stimulates cortisol and prolactin. It has not been developed into an approved pharmaceutical. Long-term human safety data are not available from clinical trials.
GHRP-6 activates the ghrelin receptor — the same receptor that the hunger hormone ghrelin itself activates. When this receptor is activated in the pituitary, it triggers growth hormone release. When it is activated in the hypothalamus (the brain region that regulates hunger), it stimulates appetite. GHRP-6 activates both locations, which is why it both increases GH and causes a noticeable increase in hunger. Researchers discovered GHRP-6 before ghrelin was identified, and studying GHRP-6 was actually part of how scientists eventually found and characterized the ghrelin receptor and then ghrelin itself. This makes GHRP-6 historically important in GH and hunger hormone research even though it predated understanding of its own mechanism.
GHRP-6 is not FDA-approved. The appetite stimulation is a consistent and notable effect at research doses. Cortisol and prolactin elevations occur alongside GH release. The same general considerations about elevated GH apply as with other GH secretagogues. Research use should account for the hunger stimulation effect, which can be significant and is relevant to any study involving body composition or metabolic endpoints.
Moderate Evidence
This compound has been studied in Phase 1 or Phase 2 human trials. Evidence is encouraging but more large-scale trials are needed.
Published Research Ranges
100–300mcg 2–3x daily in research protocols
Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.
Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.
GHRP-6 Stimulates GH Secretion via Ghrelin Receptor Activation
Jasmonates: biosynthesis, perception, signal transduction and action in plant stress response, growth and development. An update to the 2007 review in Annals of Botany
Growth hormone-releasing activity of growth hormone-releasing peptide-6 is maintained after short-term oral pretreatment with the hexapeptide in normal aging
Growth Hormone Deficiency Following Traumatic Brain Injury in Pediatric and Adolescent Patients: Presentation, Treatment, and Challenges of Transitioning from Pediatric to Adult Services
Research Education Only: This profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions.
We use cookies to enhance your research experience and analyze platform usage. By continuing, you agree to our Cookie Policy.